ShanXi C&Y Pharmaceutical Group Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
ShanXi C&Y Pharmaceutical Group Co., Ltd. carries a market capitalization of 2.19B, placing it among publicly traded companies globally. Its enterprise value stands at 3.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.19B |
| Enterprise Value | 3.26B |
Share Statistics
ShanXi C&Y Pharmaceutical Group Co., Ltd. currently has 256.06M shares outstanding.
| Shares Outstanding | 256.06M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
ShanXi C&Y Pharmaceutical Group Co., Ltd. trades at a trailing price-to-earnings ratio of 276.31. The price-to-sales ratio is 4.41, and the price-to-book ratio stands at 63.86.
| PE Ratio | 276.31 |
| PS Ratio | 4.41 |
| PB Ratio | 63.86 |
| P/TBV Ratio | 1,693.17 |
| P/FCF Ratio | 122.94 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, ShanXi C&Y Pharmaceutical Group Co., Ltd. trades at an EV/EBITDA multiple of 51.85 and an EV/FCF ratio of 117.66. The EV/Sales ratio of 5.22 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 51.85 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.22 |
| EV / EBITDA | 51.85 |
| EV / EBIT | 51.85 |
| EV / FCF | 117.66 |
Financial Position
ShanXi C&Y Pharmaceutical Group Co., Ltd. maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 111.21, indicating elevated leverage, while an interest coverage ratio of 4.10 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 0.98 |
| Quick Ratio | 0.24 |
| Debt / Equity | 111.21 |
| Debt / EBITDA | 9.09 |
| Interest Coverage | 4.10 |
Financial Efficiency
ShanXi C&Y Pharmaceutical Group Co., Ltd. posts a return on equity of -13.67 and a return on invested capital of 1.94.
| Return on Equity (ROE) | -13.67 |
| Return on Assets (ROA) | -0.27 |
| Return on Invested Capital (ROIC) | 1.94 |
| Return on Capital Employed (ROCE) | -2.27 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.39 |
Taxes
Over the trailing twelve months, ShanXi C&Y Pharmaceutical Group Co., Ltd. has paid 27.06M in income taxes, reflecting an effective tax rate of 67.43.
| Income Tax | 27.06M |
| Effective Tax Rate | 67.43 |
Stock Price Statistics
ShanXi C&Y Pharmaceutical Group Co., Ltd.'s stock has declined approximately -16.76413% over the past 52 weeks. The 50-day moving average sits at 11.26, while the 200-day moving average is 11.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | -16.76413% |
| 50-Day Moving Average | 11.26 |
| 200-Day Moving Average | 11.11 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ShanXi C&Y Pharmaceutical Group Co., Ltd. generated 624.37M in revenue and converted that into -4.14M in net income, yielding earnings per share of 0.05. EBITDA reached 62.87M, while operating income came in at 62.87M.
| Revenue | 624.37M |
| Gross Profit | 419.49M |
| Operating Income | 62.87M |
| Pretax Income | 40.13M |
| Net Income | -4.14M |
| EBITDA | 62.87M |
| EBIT | 62.87M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
ShanXi C&Y Pharmaceutical Group Co., Ltd. holds 137.61M in cash and equivalents against 571.71M in total debt, resulting in a net debt position of 238.05M. Total book value stands at 43.09M, with working capital of -8.77M providing operational flexibility.
| Cash & Cash Equivalents | 137.61M |
| Total Debt | 571.71M |
| Net Debt | 238.05M |
| Equity (Book Value) | 43.09M |
| Book Value Per Share | 0.18 |
| Working Capital | -8.77M |
Cash Flow
After subtracting -22.71M in capital expenditures, free cash flow totaled -22.71M - equivalent to -0.09 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -22.71M |
| Free Cash Flow | -22.71M |
| FCF Per Share | -0.09 |
Margins
ShanXi C&Y Pharmaceutical Group Co., Ltd. operates with a gross margin of 67.19, reflecting its pricing power and cost economics. The operating margin of 10.07 and net profit margin of -0.66 provide insight into operational efficiency.
| Gross Margin | 67.19 |
| Operating Margin | 10.07 |
| Pretax Margin | 6.43 |
| Profit Margin | -0.66 |
| EBITDA Margin | 10.07 |
Dividends & Yields
The company's payout ratio of 43.27 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.05 |
| Dividend Yield | N/A |
| Payout Ratio | 43.27 |
| Shareholder Yield | -4.36 |
| FCF Yield | 0.81 |
Stock Splits
ShanXi C&Y Pharmaceutical Group Co., Ltd.'s most recent stock split took place on July 8, 2016 with a 5:6 split ratio.
| Last Split Date | 7/8/2016 |
| Split Ratio | 5:6 |
Scores
ShanXi C&Y Pharmaceutical Group Co., Ltd. posts an Altman Z-Score of 2.02, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.02 |